uniqure amt-130 news - Search News

FDA, uniQure and Accelerated Approval

Seeking Alpha on MSN · 1d

uniQure stock rockets 90% on FDA update for AMT-130

UniQure (NASDAQ:QURE) stock shot up 90% Tuesday morning on news that the company had reached an agreement with the FDA on key elements for an accelerated approval pathway for its drug AMT-130 in the treatment of Huntington’s disease.

Business Insider · 1d

uniQure announces alignment with FDA on elements of approval path for AMT-130

N.V. announced that the company reached agreement with the U.S. Food and Drug Administration, FDA, on key elements of an

hdbuzz.net · 1d

Moving into the Fast Lane: uniQure and the FDA Are on the Same Track for Accelerated Approval

In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of drugs for Huntington’s disease.

pharmaphorum18h

uniQure rockets on map to market for Huntington's therapy

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

BioPharma Dive1d

UniQure shares soar on chance of speedy approval for Huntington’s therapy

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

Hosted on MSN1d

uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels ...

1d

Why Is uniQure Stock Skyrocketing On Tuesday?

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results